Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: Implications for drug design

Journal of Medicinal Chemistry

Volumn 43, Issue 18, 2000, Pages 3377-3385

  Gavuzzo, E ^a   Pochetti, G ^a   Mazza, F ^a,b   Gallina, C ^c   Gorini, B ^d   D'Alessio, S ^e   Pieper, M ^f   Tschesche, H ^f   Tucker, P A ^g  

^a CNR   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Polifarma Research Center   (Italy)

^f BIELEFELD UNIVERSITY   (Germany)

^g EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (BIPHENYL 4 YLSULFONYL) 1,2,3,4 TETRAHYDROISOCHINOLIN 3 CARBOXYLIC ACID; BIPHENYL DERIVATIVE; ENZYME INHIBITOR; NEUTROPHIL COLLAGENASE; PHOSPHONIC ACID DERIVATIVE; TRYPTOPHAN; UNCLASSIFIED DRUG; ZINC ION;

ARTICLE; BINDING SITE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BINDING; DRUG DESIGN; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME SPECIFICITY; ENZYME STABILITY; ENZYME STRUCTURE; MOLECULAR INTERACTION; X RAY CRYSTALLOGRAPHY;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; ISOQUINOLINES; LIGANDS; MATRIX METALLOPROTEINASE 8; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OLIGOPEPTIDES; PHOSPHONIC ACIDS; PROTEASE INHIBITORS; PROTEIN BINDING; SULFONES; TETRAHYDROISOQUINOLINES;

EID: 0034618636     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9909589     Document Type: Article

References (60)

1. Localization of messenger RNA for M(r) 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization
2. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders
3. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury
4. Matrix metalloproteinase inhibitors 1998
5. Remodeling MMPIs. Matrix metalloproteinase inhibitors will be approved as drugs, probably this year, but questions remain concerning their specificity, bioavailability, and potential long-term toxicity
6. Structure of astacin with a transition-state analogue inhibitor
7. Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinanses: A structure - Activity study
8. 2 Å X-ray structure of adamalysin II complexed with a peptide phosphonate inhibitor adopting a retro-binding mode
9. Inhibition of adamalysin II and MMPs by phosphonate analogues of snake venom peptides
10. Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor α convertase inhibitors
11. Phosphonate inhibitors of adamalysin II and matrix metalloproteinases
12. Cyclic and heterocyclic N-substituted α-iminohydroxamic and carboxylic acids
13. Relative configuration and conformation of key intermediates for matrix metalloproteinase inhibitors as determined by NMR-based restrained simulated annealing and validated by X-ray anlysis
14. A new approach to receptor ligand design: Synthesis and conformation of a new class of potent and highly selective μ opioid antagonists utilizing tetrahydroisoquinoline carboxylic acid
15. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific μ opioid receptor antagonists with greatly reduced binding at somatostatin receptors
16. Topographic design of peptide neurotransmitters and hormones on stable backbone templates: Relation of conformation and dynamics to bioactivity
17. Constrained phenylalanine analogues. Preferred conformation of the 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) residue
18. New amino acids for the topographical control of peptide conformation: Synthesis of all the isomers of α,β-dimethylphenylalanine and α,β-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid of high optical purity
19. Design and synthesis of side-chain conformationally restricted phenylalanines and their use for structure-activity studies on tackykinin NK-1 receptor
20. 8] bradykinin
21. Use of conformationally constrained peptides for a topographical analysis of the combining site of a monoclonal anti-substance P antibody
22. Matrix metalloproteinase inhibitors: A structure-activity study
23. Structure and conformation of peptides containing the sulfonamide junction
24. 2
25. Structure and conformation of peptides containing the sulfonamide junction. IV. Synthesis and crystal conformation of N-benzoyl-L-phenylalanyl-tauryl-L-leucine methyl ester
26. Peptides containing the sulfonamide junction: Synthesis, structure, and conformation of Z-Tau-Pro-Phe-NHiPr
27. Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis
28. Inhibitors of metalloproteases
29. A new method for synthesis of peptides: Activation of the carboxyl group with dicyclohexylcarbodiimide using 1-hydroxybenzotriazoles as additives
30. An efficient synthesis of N-α-Fmoc-4-(phosphonodifluoromethyl)-L-phenylalanine
31. New α-amino phosphonic acid derivatives of vinblastine: Chemistry and antitumor activity
32. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity
33. Structural implications for the role of the N terminus in the 'superactivation' of collagenases
34. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design
35. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor
36. Stromelysin-1: Three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme
37. 1 specificity pocket
38. Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor
39. 1.8-Å crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile
40. Structure of malonic acid-based inhibitors bound to human neutrophil collagenase. A new binding mode explains apparently anomalous data
41. Matrix metalloproteinase inhibitors: Current status
42. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR
43. Molecular recognition in nicotinic acethylcholine receptors: The importance of π-cation interactions
44. Cation-π interaction between the trimethylammonium moiety and the aromatic ring within indole-3-acetic acid choline ester, a model compound for molecular recognition between acetylcholine and its esterase: An X-ray study
45. Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp
46. The cation-π interaction
47. HIV-1 integrase pharmacophore: Discovery of inhibitors through three-dimensional database searching
48. Molecular recognition of protein - Ligand complexes: Applications to drug design
49. Peptide chain structure parameters, bond angles and conformational angles from the Cambridge Structural Database
50. The Cambridge crystallographic data center: Computer-based search, retrieval, analysis and display of information
51. The metzincins. Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases
52. Sequence specificities of human fibroblast and neutrophil collagenases
53. Substrate specificity of the human matrix metalloproteinase stromelysin and the development of continuous fluorometric assays
54. Comparative sequence specificities of human 72- and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin)
55. Hydroxamate derivatives of substrate-analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases
56. The recombinant catalytic domain of human neutrophil collagenase lacks type I collagen substrate specificity
57. Processing of X-ray diffraction data collection in oscillation mode
58. SHELXL: High-resolution refinement
59. Improved methods for building protein models in electron density maps and the location of errors in these models